UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease

The Journal of Prevention of Alzheimer's Disease, 2022, Vol.9 (2), p.197-210

2022

Volltextzugriff (PDF)

Radiative corrections to the average bremsstrahlung energy loss of high-energy muons

Physics letters. B, 2018-01, Vol.776 (C), p.350-354

2018

Volltextzugriff (PDF)

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS

Neurology, 2007-04, Vol.68 (17), p.1390-1401

2007

Volltextzugriff (PDF)

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

Neurology, 2009-03, Vol.72 (9), p.806-812

2009

Volltextzugriff (PDF)

Theoretical uncertainties of muon transport calculations for very large volume neutrino telescopes

Journal of physics. Conference series, 2020-12, Vol.1690 (1), p.12005

2020

Volltextzugriff (PDF)

PROPOSAL: A library to propagate leptons and high energy photons

Journal of physics. Conference series, 2020-12, Vol.1690 (1), p.12021

2020

Volltextzugriff (PDF)

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

The New England journal of medicine, 2006-03, Vol.354 (9), p.899-910

2006

Volltextzugriff (PDF)

Feasibility study to measure the muon bremsstrahlung cross section with the energy loss profile using neutrino telescopes

Journal of physics. Conference series, 2020-12, Vol.1690 (1), p.12020

2020

Volltextzugriff (PDF)

Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite

Neurology, 2003-11, Vol.61 (10), p.1367-1373

2003

Volltextzugriff (PDF)

Festschrift für Günther Beitzke zum 70. Geburtstag am 26. April 1979

Otto Sandrock / Otto Sandrock

2020

Volltextzugriff (PDF)

Maintenance of Acetylcholine Receptor Number by Neuregulins at the Neuromuscular Junction in Vivo

Science (American Association for the Advancement of Science), 1997-04, Vol.276 (5312), p.599-603

1997

Volltextzugriff (PDF)

Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease

The journal of prevention of Alzheimer's disease, 2017, Vol.4 (4), p.255-263

2017

Volltextzugriff (PDF)

Assessing disability progression with the Multiple Sclerosis Functional Composite

Multiple sclerosis, 2009-08, Vol.15 (8), p.984-997

2009

Volltextzugriff (PDF)

Scottish Colonial Literature: Writing the Atlantic, 1603-1707

Sandrock, Kirsten

1, 2021

Volltextzugriff (PDF)

Neutralizing antibodies and efficacy of interferon β-1a: A 4-year controlled study

Neurology, 2005-07, Vol.65 (1), p.40-47

2005

Volltextzugriff (PDF)

Diffractive Scattering of Virtual Photons on Nuclei and Its Interference with the Muon-Induced Bremsstrahlung Process

Physics of atomic nuclei, 2021, Vol.84 (1), p.87-91

2021

Volltextzugriff (PDF)

Benefit of interferon β-1a on MSFC progression in secondary progressive MS

Neurology, 2002-09, Vol.59 (5), p.679-687

2002

Volltextzugriff (PDF)

Elevated 1-Year Mortality Rate in Males Sustaining Low-Energy Proximal Femur Fractures and Subgroup Analysis Utilizing Age-Adjusted Charlson Comorbidity Index

Geriatric orthopaedic surgery & rehabilitation, 2020, Vol.11, p.2151459319898644-2151459319898644

2020

Volltextzugriff (PDF)

Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy

Neurology, 2010-02, Vol.74 (8), p.651-657

2010

Volltextzugriff (PDF)

Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis

The New England journal of medicine, 2000-09, Vol.343 (13), p.898-904

2000

Volltextzugriff (PDF)

Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab

The Journal Of Prevention of Alzheimer's Disease, 2023, Vol.10 (2), p.171-177

2023

Volltextzugriff (PDF)

Randomized, placebo-controlled, phase 1b study of anti-beta-amyloid antibody aducanumab (biib037) in prodromal ad/mild ad dementia: Interim results by patient subgroup

Journal of the neurological sciences, 2015-10, Vol.357, p.e10-e10

2015

Volltextzugriff (PDF)

Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients

Multiple sclerosis, 2005-12, Vol.11 (6), p.626-634

2005

Volltextzugriff (PDF)

A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS

Neurology, 2002-11, Vol.59 (10), p.1507-1517

2002

Volltextzugriff (PDF)

Gender effects on intramuscular interferon beta-1a in relapsing–remitting multiple sclerosis: analysis of 1406 patients

Multiple sclerosis, 2011-03, Vol.17 (3), p.353-360

2011

Volltextzugriff (PDF)

1 – 25 von 1.215

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(892)
Mit Volltextzugriff
(966)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(478)
Life Sciences & Biomedicine
(340)
Humans
(267)
Male
(120)
Female
(117)
Biological And Medical Sciences
(108)
Animals
(107)
Physical Sciences
(94)
Adult
(83)
Technology
(80)
Medical Sciences
(76)
Middle Aged
(69)
Chemistry
(57)
Mice
(44)
Physics
(41)
Exact Sciences And Technology
(39)
Neurosciences & Neurology
(39)
General & Internal Medicine
(38)
Fundamental And Applied Biological Sciences. Psychology
(36)
International Law
(36)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neurology
(25)
Journal Of Alloys And Compounds
(24)
Chest
(19)
Cheminform
(16)
Catholic World
(14)
The New England Journal Of Medicine
(14)
Alzheimer's & Dementia
(12)
Intensive Care Medicine
(12)
Journal Of The Less-Common Metals
(12)
Annals Of Neurology
(11)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease

Radiative corrections to the average bremsstrahlung energy loss of high-energy muons

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

Theoretical uncertainties of muon transport calculations for very large volume neutrino telescopes

PROPOSAL: A library to propagate leptons and high energy photons

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Feasibility study to measure the muon bremsstrahlung cross section with the energy loss profile using neutrino telescopes

Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite

Festschrift für Günther Beitzke zum 70. Geburtstag am 26. April 1979

Maintenance of Acetylcholine Receptor Number by Neuregulins at the Neuromuscular Junction in Vivo

Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease

Assessing disability progression with the Multiple Sclerosis Functional Composite

Scottish Colonial Literature: Writing the Atlantic, 1603-1707

Neutralizing antibodies and efficacy of interferon β-1a: A 4-year controlled study

Diffractive Scattering of Virtual Photons on Nuclei and Its Interference with the Muon-Induced Bremsstrahlung Process

Benefit of interferon β-1a on MSFC progression in secondary progressive MS

Elevated 1-Year Mortality Rate in Males Sustaining Low-Energy Proximal Femur Fractures and Subgroup Analysis Utilizing Age-Adjusted Charlson Comorbidity Index

Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy

Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis

Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab

Randomized, placebo-controlled, phase 1b study of anti-beta-amyloid antibody aducanumab (biib037) in prodromal ad/mild ad dementia: Interim results by patient subgroup

Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients

A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS

Gender effects on intramuscular interferon beta-1a in relapsing–remitting multiple sclerosis: analysis of 1406 patients

Suchergebnisse filtern